News Release：2026 | Eisai Co., Ltd.

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.

2026 Release

April 21, 2026
- R&D
- Products
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
March 27, 2026
- R&D
- Products
Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27, 2026
- R&D
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
Additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories
Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer
March 26, 2026
- Corporate
Notice of Nominees for Directors
March 23, 2026
- R&D
- Products
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
March 19, 2026
- Products
Regarding Discontinuation of Administration of “Tazverik® Tablets 200mg” (tazemetostat hydrobromide)
March 17, 2026
- Corporate
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 12, 2026
- Corporate
- Ecosystem
Have Fun Exploring Sleep with Pokémon!
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration
March 11, 2026
- R&D
- Products
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
March 2, 2026
- R&D
- Products
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a multi-targeted tyrosine kinase inhibitor in combination with a HIF-2 alpha inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor

Based on these data, the U.S. FDA accepts for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC
February 16, 2026
- R&D
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 9, 2026
- Corporate
Eisai Announces Appointment of Corporate Officers
February 9, 2026
- R&D
- Products
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
February 6, 2026
- Corporate
- Products
Revenue of LEQEMBI® (Preliminary Basis)
February 5, 2026
- Corporate
- R&D
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
January 26, 2026
- R&D
- Products
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease

FDA action date set for May 24, 2026
January 21, 2026
- Corporate
- Sustainability
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE TENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
January 13, 2026
- Corporate
- R&D
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, the Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India

Nuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to €195 million (approx. USD $230 million) in upfront and milestone payments

Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer
January 13, 2026
- Corporate
Changes of Corporate Officers
January 6, 2026
- R&D
- Products
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer
an at-home injection from the initiation of treatment for this progressive, relentless disease